Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Canadian-under $3.00 Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: Miner who wrote (10209)	11/23/2002 4:16:43 PM
From: Al Collard	Respond to of 11802

Hi John, Your in with DMX-t @$ 1.99 for 5,025 shares. Chart for Dimethaid Research, Inc: stockcharts.com[w,a]dacaniay[dc][pc20!b50!f][vc60][iLa12,26,9!Ll14]&pref=G From the chart of DMX we can see the stock broke up on Friday and is now testing the resistance of it's 20EMA. The chart indicators have turned very bullish as both the MACD and the ADX have crossed over. Looks good John. I will put this stock on my ticker for next week to take a closer look. Good luck with this pick, Al

To: Miner who wrote (10209)	11/25/2002 7:31:08 AM
From: Al Collard	Respond to of 11802

DMX-t...in the news: Globe says Dimethaid on a slow road to who knows where Mon 25 Nov 2002 The Globe and Mail reports in its Monday, Nov. 25 edition that Dimethaid Research chief executive officer Rebecca Keeler did not allow a single question from some 300 shareholders in attendance at the company's annual meeting last month, perhaps in an attempt to avoid the raucousness of the previous annual meeting where one shareholder called for her resignation and an independent audit of her performance. The Globe's Leonard Zehr reports that there is a running battle between Ms. Keeler and many shareholders over the seemingly endless regulatory road the company's flagship Pennsaid lotion has travelled in Canada and the United States. The Globe offers up an anonymous "biotech" source who slams the company saying, "I've never heard of anything taking that long." The Globe says Dimethaid is a story about undisclosed late-stage testing of Pennsaid, unexplained trading by insiders, the departure of two auditing firms and a European marketing strategy that is running a year behind schedule. John Totten, a shareholder who jumped ship in the $5 range, says Dimethaid "is a good company ... that is being destroyed by the CEO." Dimethaid stock jumped 14 cents to close at $1.99 Friday in Toronto.

To: Miner who wrote (10209)	11/25/2002 7:54:17 AM
From: Al Collard	Respond to of 11802

Globe says Dimethaid financing a dud for shareholders Mon 25 Nov 2002 The Globe and Mail reports in its Monday, Nov. 25, edition that what began as one-year bridge financing with a private New York investment bank has turned into a major headache for Dimethaid Research and has contributed to a 75-per-cent decline in its share price during the past 23 months. The Globe's Leonard Zehr writes that on the other hand, the $50-million equity line of credit from Acqua Wellington North American Equities Fund has kept Dimethaid afloat this year as it waits for regulatory approval of its Pennsaid topical lotion for arthritic pain. The deal, which expires at the end of this month, allows Dimethaid to call on Acqua for cash in exchange for new stock. The Globe says Dimethaid has only $5-million left to draw from Acqua, meaning the company, which has monthly expenses of $1.3-million, could run out of money in February. What irks many investors is that Acqua currently owns only 1.56 million shares of the 5.9 million it has purchased from Dimethaid. Acqua says it is not in its mandate to control companies. An unnamed former insider says Acqua's stock sales have allowed Dimethaid to "finance itself on the back of retail investors without having to issue a prospectus."